Research programme: long-acting conjugate therapeutics - Hanmi Pharmaceutical

Drug Profile

Research programme: long-acting conjugate therapeutics - Hanmi Pharmaceutical

Alternative Names: HM 11760A; HM 1216OB; HM 12260b; LAPS-FSH; LAPS-IFNβ

Latest Information Update: 08 Jul 2013

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Blood coagulation factors; Erythropoietins; Follicle stimulating hormones; Glucagon-like peptides; Granulocyte colony-stimulating factors; Growth hormones; Interferons; Peptides
  • Mechanism of Action Blood coagulation factor replacements; Corticotropin-releasing factor antagonists; Erythropoiesis stimulants; Factor X stimulants; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Granulocyte colony stimulating factor stimulants; Growth hormone releasing factor antagonists; Intercellular signalling peptide and protein stimulants; Interferon alpha stimulants; Interferon beta stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia; Cancer; Growth disorders; Haemophilia; Hepatitis C; Infertility; Multiple sclerosis; Neutropenia; Obesity; Type 2 diabetes mellitus
  • Research Acromegaly

Most Recent Events

  • 03 May 2013 Preclinical trials in Type-2 diabetes mellitus in South Korea (Parenteral)
  • 03 May 2013 Preclinical trials in Obesity in South Korea (Parenteral)
  • 09 Aug 2010 Preclinical trials in Infertility in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top